Mariana Sbaraini da Silva1, Mariana Lazo2,3, Natalie R Daya4, Olive Tang4, Beatriz D Schaan1,5, Christie M Ballantyne6, Chiadi Ndumele4, Elizabeth Selvin4. 1. Postgraduate Program in Cardiology and Cardiovascular Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grade do Sul, Brazil. 2. Department of Medicine, Division of General Internal Medicine, Johns Hopkins University, Baltimore, Maryland, USA. 3. Department of Community Health and Prevention, Urban Health Collaborative, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania, USA. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 5. Department of Endocrinology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grade do Sul, Brazil. 6. Department of Medicine, Baylor College of Medicine, and Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
Abstract
OBJECTIVE: The aim of this study was to study the prospective association between N-terminal pro-brain natriuretic peptide (NT-proBNP) and changes in weight and obesity risk in a community-based population. METHODS: Data from 9,681 participants from the Atherosclerosis Risk in Communities Study were analyzed at two time points 6 years apart. Among people without obesity at baseline, multivariable logistic regression models were used to examine the association between baseline levels of NT-proBNP and incident obesity. A multivariable linear regression model was used to examine the association between changes in NT-proBNP (visit 2 serum and visit 4 plasma samples) and changes in weight. RESULTS: The prevalence of obesity increased from 28% to 35% in the 6-year follow-up period. Compared with individuals in the highest NT-proBNP quartile, those in the lowest were more likely to have obesity at baseline (odds ratio 1.25; 95% CI: 1.08-1.45) and, among people who did not have obesity at baseline, were more likely to develop obesity at follow-up (odds ratio 1.35; 95% CI: 1.07-1.69). Changes in NT-proBNP were inversely associated with weight change. CONCLUSIONS: In this prospective study, lower levels of NT-proBNP were associated with higher risk of obesity, and changes in NT-proBNP were inversely associated with changes in weight. This suggests that natriuretic peptides or their pathways may be potential targets in the treatment of obesity.
OBJECTIVE: The aim of this study was to study the prospective association between N-terminal pro-brain natriuretic peptide (NT-proBNP) and changes in weight and obesity risk in a community-based population. METHODS: Data from 9,681 participants from the Atherosclerosis Risk in Communities Study were analyzed at two time points 6 years apart. Among people without obesity at baseline, multivariable logistic regression models were used to examine the association between baseline levels of NT-proBNP and incident obesity. A multivariable linear regression model was used to examine the association between changes in NT-proBNP (visit 2 serum and visit 4 plasma samples) and changes in weight. RESULTS: The prevalence of obesity increased from 28% to 35% in the 6-year follow-up period. Compared with individuals in the highest NT-proBNP quartile, those in the lowest were more likely to have obesity at baseline (odds ratio 1.25; 95% CI: 1.08-1.45) and, among people who did not have obesity at baseline, were more likely to develop obesity at follow-up (odds ratio 1.35; 95% CI: 1.07-1.69). Changes in NT-proBNP were inversely associated with weight change. CONCLUSIONS: In this prospective study, lower levels of NT-proBNP were associated with higher risk of obesity, and changes in NT-proBNP were inversely associated with changes in weight. This suggests that natriuretic peptides or their pathways may be potential targets in the treatment of obesity.
Authors: Lori B Daniels; Paul Clopton; Vikas Bhalla; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Philippe G Steg; Arne Westheim; Cathrine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough; Alan S Maisel Journal: Am Heart J Date: 2006-05 Impact factor: 4.749
Authors: Robert H Christenson; Hassan M E Azzazy; Show-Hong Duh; Susan Maynard; Stephen L Seliger; Christopher R Defilippi Journal: Clin Chem Date: 2010-02-18 Impact factor: 8.327
Authors: Andreas L Birkenfeld; Michael Boschmann; Cedric Moro; Frauke Adams; Karsten Heusser; Gabriele Franke; Michel Berlan; Friedrich C Luft; Max Lafontan; Jens Jordan Journal: J Clin Endocrinol Metab Date: 2005-03-01 Impact factor: 5.958
Authors: Erika F Brutsaert; Mary L Biggs; Joseph A Delaney; Luc Djoussé; John S Gottdiener; Joachim H Ix; Francis Kim; Kenneth J Mukamal; David S Siscovick; Russell P Tracy; Ian H de Boer; Christopher R deFilippi; Jorge R Kizer Journal: Metabolism Date: 2016-06-24 Impact factor: 8.694
Authors: Eric Plante; Ahmed Menaouar; Bogdan A Danalache; Tom L Broderick; Marek Jankowski; Jolanta Gutkowska Journal: Diabetologia Date: 2014-03-05 Impact factor: 10.122